As Myc is required for gastric tumour growth, it also informs future clinical trials with putative Myc inhibitors that the gastric epithelium can tolerate the loss of Myc. Future investigations into the differences between the intestinal and gastric epithelium could help uncover why the intestine is more sensitive to deregulated Wnt, and explore if Wnt inhibitors elicit a different response from these two tissues thus identifying new oncogenes/tumour suppressors in both cancer types. This evidence concerns the gene MYC and neoplasm.